SYNTHETIC RECORD, NOT A REAL MEDICAL RECORD — Progress Note 3 — Focused Visit (Follow-up) — Ernest Hemingway

PatientErnest Hemingway
Date of birth1970-07-21
IdentifiersMRN HR-ET003-SYN; SSN (made up) 000-03-7419
Document date2026-04-13
AuthorWalter Brandt-Ochoa, MD
CustodianSt. Posthumous Health Center

Readable copy of the C-CDA narrative, generated with the XML. Coded entries are in the XML file beside this page.

Chief Complaint

Six-week review: phlebotomy, drinking, mood and liver MRI. [S]

History of Present Illness

Mr. Hemingway returns six weeks after intake. He has had three weekly phlebotomies without dizziness, and the fourth is planned after today's blood tests. His MRI this morning has been reported. He is drinking three or four drinks a day, all in the evening, with naltrexone daily; his AUDIT-C for the past month is 7. He has had no tremor or sweats. His mood is a little better but he still wakes early and finds it hard to start writing; his PHQ-9 is 13. Sertraline 50 mg causes no side effects. Home blood pressure averages 136/84. Headaches are about twice a week. His guns remain at the club. The echocardiogram ordered at intake has not been scheduled yet. [S]

ElementDetail
PhlebotomyThree sessions; the fourth today
AlcoholThree or four drinks a day, evenings only; AUDIT-C 7
MoodPHQ-9 13; item 9 scored 0
Home blood pressureAverage 136/84
MRI of the liverLiver iron about 9.8 mg/g; stiffness 3.1 kPa; no lesion

Review of Systems

SystemResultFinding
ConstitutionalNegativeNo dizziness after phlebotomy; tiredness a little better
GastrointestinalNegativeNo abdominal pain, nausea or jaundice
NeurologicalPositiveHeadaches about twice a week; no tremor
PsychiatricPositiveEarly waking and low drive in the mornings; no thoughts of suicide or wishes to be dead since the last visit

4 systems reviewed. [S]

Medications

MedicationFrequencyRouteDatesStatusEvidence
Naltrexone 50 mg oral tablet, one tablet daily, to reduce heavy drinkingOne tablet dailyOral route2026-03-02activeS
Thiamine 100 mg oral tablet, one tablet dailyOne tablet dailyOral route2026-03-02 to 2026-08-31completedS
Sertraline 50 mg oral tablet, one tablet dailyOne tablet dailyOral route2026-03-02 to 2026-04-13completedS
Sertraline 100 mg oral tablet, one tablet dailyOne tablet dailyOral route2026-04-13activeS
Amlodipine 5 mg oral tablet, one tablet dailyOne tablet dailyOral route2026-03-02 to 2026-06-08completedS

Allergies and Intolerances

AllergyReactionStatusEvidence
No known allergyactiveS

Vital Signs

DateMeasureValueUnitProvenance
2026-04-13Body height183cmS
2026-04-13Body weight96.2kgS
2026-04-13Body mass index (BMI) [Ratio]28.7kg/m2S
2026-04-13Systolic blood pressure138mm[Hg]S
2026-04-13Diastolic blood pressure86mm[Hg]S
2026-04-13Heart rate80/minS
2026-04-13Respiratory rate16/minS
2026-04-13Body temperature36.6CelS
2026-04-13Oxygen saturation in Arterial blood by Pulse oximetry97%S

Results

DateMeasureValueUnitReference rangeFlagProvenance
2026-04-13Hemoglobin [Mass/volume] in Blood14.2g/dL13.5-17.5 g/dLNormalS
2026-04-13MCV [Entitic mean volume] in Red Blood Cells by Automated count99fL80-100 fLNormalS
2026-04-13Aspartate aminotransferase [Enzymatic activity/volume] in Serum or Plasma41U/L10-40 U/LHighS
2026-04-13Alanine aminotransferase [Enzymatic activity/volume] in Serum or Plasma49U/L7-55 U/LNormalS
2026-04-13Gamma glutamyl transferase [Enzymatic activity/volume] in Serum or Plasma104U/L8-61 U/LHighS
2026-04-13Ferritin [Mass/volume] in Serum or Plasma1180ng/mL24-336 ng/mLHighS
2026-04-13Patient Health Questionnaire 9 item (PHQ-9) total score [Reported]13{score}S
2026-04-13Total score [AUDIT-C]7{score}S

Physical Exam

Vital signs recorded on 2026-04-13; see the Vital Signs section. [S]

SystemFinding
GeneralWell; blood pressure 138/86, pulse 80; weight 96.2 kg
CardiovascularRegular rhythm; no murmur
AbdomenLiver edge just palpable, smooth; no spleen felt
NeurologicalNo tremor
PsychiatricEngaged; mood low but brighter; no psychotic features

Problems

ProblemClinical statusVerificationCodeProvenance
Alcohol use disorder, severe; heavy daily drinking for most of his adult life; synthetic modern episode linked to his documented heavy drinkingactiveconfirmed F10.20S — Synthetic modern coding of DSM-5-TR severe alcohol use disorder (seven criteria); person-first language; not a claim about his real diagnosis.
Raised transferrin saturation and ferritin found on routine intake tests, cause not yet known (heavy drinking, liver disease or iron overload)resolvedconfirmed R79.0S — Synthetic presenting finding; superseded when HFE testing gave the diagnosis.
Hereditary hemochromatosis, HFE C282Y homozygous, with iron overload (ferritin over 1,000 ng/mL) and no advanced liver fibrosis on imagingactiveconfirmed E83.110S — Synthetic modern diagnosis. Whether he had hemochromatosis is disputed (CLM-0013); the modern diagnosis is not offered as proof of it.
Major depressive disorder, single episode, moderate; Mood Disorder Questionnaire negative and no history of mania or hypomaniaactiveconfirmed F32.1S — Synthetic modern diagnosis; not a claim about his real mood. The roster's bipolar disorder lead is disputed (CLM-0014) and is not used.
Essential hypertension, stage 2, with heavy drinking contributingactiveconfirmed I10S — Synthetic modern diagnosis confirmed by home readings.
Post-concussion symptoms (headaches, slowed thinking and forgetfulness) after repeated head injuries, most recently a concussion with a skull fracture a year ago; chronic traumatic encephalopathy is not diagnosedactiveconfirmed F07.81S — Synthetic modern diagnosis anchored to his documented head injuries; alcohol and depression also affect the symptoms.
Prediabetes (HbA1c 6.1%)activeconfirmed R73.03S — Synthetic finding on diabetes screening; iron overload and alcohol both raise the risk of diabetes.

Assessment and Plan

Protocol monitoring: items the monitoring protocol calls for at this visit. [S]

DomainMeasureIntervalStatusDetail
LaboratoryHemoglobin before each phlebotomy (hold if under 12.0 g/dL)Before every session; full blood count at visitsCompleted todayHemoglobin 14.2 g/dL, MCV 99 fL; all pre-session checks above 13.5
LaboratorySerum ferritin during induction phlebotomyAt diagnosis, then about every 10 to 12 phlebotomies; target 50 to 100 ng/mLCompleted todayFerritin 1,180 ng/mL after three sessions
Medication safetyWeekly phlebotomy of 500 mLWeekly during inductionCompleted todayThree sessions; the fourth today
ImagingLiver fibrosis staging (ferritin over 1,000 ng/mL and raised ALT)Once at diagnosis: elastography, MRI or biopsyCompleted todayMRI today: liver iron about 9.8 mg Fe/g; stiffness 3.1 kPa, mild fibrosis; no advanced fibrosis; no lesion
ImagingLiver cancer surveillanceEvery six months only with cirrhosis or advanced fibrosisNot indicatedNo cirrhosis or advanced fibrosis on MRI
Self-managementDiet: no iron or vitamin C supplements, no raw shellfishEvery visitCompleted todayNo supplements; no raw shellfish
LaboratoryLiver tests on naltrexoneBaseline, about one month, then every three to six monthsCompleted todayAST 41, ALT 49 and GGT 104 U/L at six weeks on naltrexone
SurveyDrinking quantity and goal (AUDIT-C, drinking diary)Every visitCompleted todayAUDIT-C 7; three or four drinks a day; he chose to stop within the month
Medication safetyOpioid use and pain plan on naltrexoneEvery visitCompleted todayNo opioids
ExaminationAlcohol withdrawal risk and symptoms when cutting down or stoppingEach visit while cutting downCompleted todayNo withdrawal signs; one drink fewer every week or so planned
Self-managementPsychosocial support for alcohol useOffer at each stageCompleted todayMutual-help group and alcohol counseling offered; he chose to work on drinking in weekly therapy
Medication safetyThiamineDaily while drinking heavilyCompleted todayTaking thiamine daily
SurveyDepression (PHQ-9)At least monthly during acute treatmentCompleted todayPHQ-9 13, item 9 scored 0; partial response
Medication safetySertraline adherence and side effectsTwo weeks after starting or changing the dose, then each visitCompleted todayNo side effects; increased to 100 mg; the behavioral health clinician checks side effects at therapy in two weeks
SurveySuicide-risk review (C-SSRS screen since the last visit), safety plan, firearm storage and the 988 Suicide & Crisis LifelineEvery visitCompleted todayC-SSRS screen negative since the last visit; firearms remain off-site
Self-managementPsychotherapy (CBT)WeeklyCompleted todayFive sessions so far
ExaminationBlood pressure, home readings, weight and cardiac auscultationEvery visitCompleted today138/86 in clinic; home average 136/84; weight 96.2 kg
ImagingEchocardiogramAt diagnosis of stage 2 hypertensionOrderedOrdered at intake; not yet scheduled; the clinic will follow it up
ExaminationPost-concussion symptoms (headache frequency, sleep, concentration)Every visitCompleted todayHeadaches about twice a week

Goal progress:

Guideline basis: Diagnosis and management of hemochromatosis: 2011 practice guideline by the American Association for the Study of Liver Diseases (2011); ACG Clinical Guideline: Hereditary Hemochromatosis (2019); The American Psychiatric Association Practice Guideline for the Pharmacological Treatment of Patients With Alcohol Use Disorder (2018); The ASAM Clinical Practice Guideline on Alcohol Withdrawal Management (2020); VA/DoD Clinical Practice Guideline for the Management of Major Depressive Disorder (2022); VA/DoD Clinical Practice Guideline for Assessment and Management of Patients at Risk for Suicide (2024); CMID: Clinical Monitoring Intelligence Database, hypertension and depression, bipolar, and mood disorders monographs (2026)

Follow-up: Weekly phlebotomy. Fourteen-week review in eight weeks with blood count, ferritin, liver tests, PHQ-9 and AUDIT-C. Weekly psychotherapy. Next scheduled visit 2026-06-08: fourteen-week review: phlebotomy, the decision to stop drinking, mood and blood pressure. [S]